Document Detail


Hepatitis B vaccine: risks and benefits of universal neonatal vaccination.
MedLine Citation:
PMID:  11474704     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Global eradication of hepatitis B, which has infected over 2000 million people worldwide, is an achievable goal. Hepatitis B vaccine is effective and safe, and is recommended in Australia as a four-dose childhood schedule commencing with a neonatal dose. A neonatal dose has a greater impact on carriage, the main reservoir of transmission, due to the inverse relationship of age and risk of chronic carriage. Universal vaccination is clearly cost-effective in countries of high hepatitis B endemicity but less so in countries of low endemicity. Other factors affecting the perceived benefits of universal vaccination in low-risk countries include the use of the preservative thiomersal in hepatitis B vaccines, and case reports of multiple sclerosis (MS) and unexplained fever in recipients. Careful epidemiological studies have failed to confirm any risk of MS or fever with the hepatitis B vaccine, which is now thiomersal-free. Other arguments against universal vaccination include 'unnecessary' vaccination of low-risk neonates. However, selective vaccination programmes targeting at-risk neonates are often poorly implemented and do not protect against horizontal transmission in early childhood. Universal vaccination, which is safe and effective, is the only practical means of achieving global eradication of hepatitis B.
Authors:
C R MacIntyre
Related Documents :
7875094 - Hepatitis b virus infection among blood donors and pregnant women in maiduguri, nigeria.
12532044 - Childhood bullous pemphigoid following hepatitis b immunization.
3922284 - Viral hepatitis vaccines.
9406564 - Vaccines for hepatitis a and b. the latest recommendations on safe and extended protect...
25030184 - Tetanus toxoids loaded glucomannosylated chitosan based nanohoming vaccine adjuvant wit...
16775624 - The nucleolus: reviewing oldies to have new understandings.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of paediatrics and child health     Volume:  37     ISSN:  1034-4810     ISO Abbreviation:  J Paediatr Child Health     Publication Date:  2001 Jun 
Date Detail:
Created Date:  2001-07-26     Completed Date:  2001-10-11     Revised Date:  2007-09-24    
Medline Journal Info:
Nlm Unique ID:  9005421     Medline TA:  J Paediatr Child Health     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  215-7     Citation Subset:  IM    
Affiliation:
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Children's Hospital at Westmead, NSW, Australia. RainaM@chw.edu.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Australia
Hepatitis / prevention & control*
Hepatitis B Vaccines / adverse effects,  therapeutic use*
Humans
Immunization Schedule
Infant Welfare
Infant, Newborn
Risk Assessment
Vaccination*
World Health
World Health Organization
Chemical
Reg. No./Substance:
0/Hepatitis B Vaccines
Comments/Corrections
Comment In:
J Paediatr Child Health. 2002 Apr;38(2):211; author reply 211-2   [PMID:  12031012 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.
Next Document:  Environmental triggers of type 1 diabetes.